Based on the recent earnings conference call transcripts, the key financial metrics for the second quarter are as follows:

Total Revenue: $326 million
- Jakafi net product revenue: $276 million, representing 33% growth over the same period last year
- Iclusig net product revenue: $16 million
- Jakavi royalties from Novartis: $34 million
- Olumiant royalties from Lilly: $1 million

Gross-to-Net Adjustment: Approximately 12% for the second quarter, with an expected full-year adjustment of approximately 13%

Cost of Product Revenue: $20 million for the quarter, including cost of goods sold for Jakafi and Iclusig, royalties to Novartis, and amortization of acquired product rights

R&D Expense: $202 million for the quarter, including $23 million in non-cash stock compensation, with a full-year guidance range of $1.050 billion to $1.150 billion due to acceleration of Phase 3 plans for epacadostat

SG&A Expense: $90 million for the quarter, including $11 million in non-cash stock compensation

Non-operating expenses: $20 million unrealized loss on long-term investments, and a one-time debt exchange expense of $1 million related to senior note conversions

Cash and Marketable Securities: Ended the second quarter with $609 million and expect to end the year with over $600 million

Full Year Guidance: In addition to the updates mentioned, an expected $15 million milestone will be recognized in the third quarter for the Japanese approval of Olumiant, resulting in up to $145 million in milestones for the year. The company now expects a net loss between $180 million to $200 million for the year, incorporating all discussed changes.

In summary, the second quarter performance reflects the strength of the underlying business and continued advancement of clinical development programs. The company continues to execute on their development plans for a robust pipeline and looks forward to updating stakeholders on progress during the third quarter call.